CompletedPhase 4

Remifentanil and Glycemic Response in Cardiac Surgery

United States116 participantsStarted 2016-01

Plain-language summary

This study evaluates the effect of using remifentanil during cardiopulmonary bypass surgery to supress the hyperglycemic response in perioperative period. Half of the participants will receive continuous intravenous remifentanil during surgery, while the other half will receive intermittent intravenous fentanyl during surgery. Intermittent intravenous fentanyl administration is this institution's standard of care.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Open cardiac surgery through sternotomy approach (coronary artery bypass, valve surgery, and any other open heart surgeries) * Surgery with use of cardiopulmonary bypass * Patients over 18 years of age * Both female and male genders * All races Exclusion Criteria: * Minimally invasive heart surgery through thoracotomy approach * Patients receiving regional analgesia such as intrathecal morphine * Patients undergoing procedures under deep hypothermic circulatory arrest * Patients with active infections such as acute infective endocarditis * Emergency surgery * Patients undergoing transplantations and ventricular assist device insertion * Patients on any mechanical circulatory support preoperatively * Patient's refusal * Allergy to remifentanil * Positive pregnancy test * Morbid obesity * End stage liver and kidney disease

What they're measuring

Blood Glucose Values (More Than One ) > 180 mg%

Timeframe: Intraoperative period

Trial details

NCT IDNCT02349152

SponsorKathirvel Subramaniam

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-12

Results submitted2017-12-22

View on ClinicalTrials.gov More Heart Diseases trials